Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing ...

AbbVie (NYSE: ABBV) shares lost ground Friday. The company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...

Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie’s monoclonal antibody Elahere (mirvetuximab soravtansine-gynx) has bagged full approval from the US Food and Drug ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

Investors have rewarded ABBV stock thanks to the uptick in its sales despite the biosimilar competition for its blockbuster ...

The FDA has granted full approval for AbbVie’s (NYSE:ABBV) drug Elahere for the treatment of ovarian cancer. AbbVie said the drug was approved to treat folate receptor alpha-positive ...